Cancer Drug Maker Dendreon Hits Ch. 11 Hoping To Sell
Cancer drug maker Dendreon Corp., which develops and markets Provenge, filed for Chapter 11 protection in Delaware on Monday, looking to either pursue a stand-alone restructuring of its roughly $650 million...To view the full article, register now.
Already a subscriber? Click here to view full article